Glioblastoma

Boston, MA

75 Glioblastoma Trials near Boston, MA

Power is an online platform that helps thousands of Glioblastoma patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

Immunotherapy Before and After Surgery for Brain Tumor

Boston, Massachusetts
This trial studies the effects of nivolumab, an immunotherapy drug, in children and young adults with severe brain cancer that has returned or worsened. The drug helps the immune system fight the cancer and may prevent it from growing.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:6 - 25

20 Participants Needed

PARP Inhibitor + Temozolomide for Brain Cancer

Boston, Massachusetts
This trial studies the safety and best dose of BGB-290 and temozolomide in treating young people with a specific type of brain tumor. BGB-290 blocks enzymes needed for tumor growth, while temozolomide kills or stops cancer cells from growing. The goal is to find out if this combination works better for these patients.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:13 - 25

78 Participants Needed

Virus-Based Drug Therapy for Brain Tumor

Boston, Massachusetts
This research study is evaluating an investigational drug, an oncolytic virus called rQNestin34.5v.2. This research study is a Phase I clinical trial, which tests the safety of an investigational drug and also tries to define the appropriate dose of the investigational drug as a possible treatment for this diagnosis of recurrent or progressive brain tumor.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

62 Participants Needed

Personalized Cancer Vaccine + RT + Pembrolizumab for Glioblastoma

Boston, Massachusetts
This research study is studying a new type of vaccine as a possible treatment for patients with glioblastoma. This research study is a Phase I clinical trial, which tests the safety of an investigational intervention and also tries to define the appropriate dose of the intervention to use for further studies. "Investigational" means that the intervention is being studied and that research doctors are trying to find more about it. It also means that the FDA (U.S. Food and Drug Administration) has not approved the Personalized NeoAntigen Cancer Vaccine for any use in patients, including people with glioblastoma. The purpose of the initial study cohort (Cohort 1) is to determine if it is possible to make and administer safely a vaccine against glioblastoma by using information gained from specific characteristics of the participants tumor. It is known that glioblastomas have mutations (changes in genetic material) that are specific to an individual patient's tumor. These mutations can cause the tumor cells to produce proteins that appear very different from the body's own cells. It is possible that these proteins used in a vaccine may induce strong immune responses, which may help the body fight any tumor cells that could cause the glioblastoma to come back in the future. Three additional cohorts (1a, 1b, \& 1c) were added to the study following completion of accrual to the original study cohort (cohort 1). Each new cohort receives NeoVax and radiation therapy as administered to cohort 1 and will also receive pembrolizumab: cohort 1a patients will start pembrolizumab w/in 2 weeks after start of RT, and continue every 3 weeks for up to 2 years; cohort 1b patients will start pembrolizumab 2-4 weeks after completion of NeoVax priming, and continue every 3 weeks for up to 2 years; cohort 1c patients will receive a single dose of pembrolizumab administered within 2 weeks after start of RT, re-start 2-4 weeks after completion of NeoVax priming, and continue every 3 weeks for up to 2 years. The rationale for adding these new cohorts is: 1) to assess the safety and feasibility of NeoVax when administered with pembrolizumab; and 2) to determine if the timing of anti-PD-1 administration impacts the immunogenicity of NeoVax. An additional sub-study cohort (1d) is being added for patients whose tumor is MGMT-methylated. Cohort 1d will enroll patients with tumors for which the MGMT status is methylated or partially methylated; patients on cohort 1d will receive standard daily temozolomide during radiation and as adjuvant therapy for up to six cycles following completion of radiation therapy. The rationale for adding cohort 1d is to determine the safety and feasibility of NeoVax when administered with pembrolizumab and temozolomide.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

56 Participants Needed

ERAS-801 for Glioblastoma

Boston, Massachusetts
This trial is testing ERAS-801, a new drug for treating brain cancer. It focuses on patients whose brain cancer has returned after treatment. The drug works by blocking signals that help cancer cells grow. Researchers want to find the safest and most effective dose of ERAS-801. ERAs may be useful for treating cancer patients.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

52 Participants Needed

RO7428731 for Glioblastoma

Boston, Massachusetts
This trial tests a new drug, RO7428731, for safety and effectiveness in patients with a specific type of brain cancer (glioblastoma) that has a particular mutation. The drug works by targeting and binding to the mutated cancer cells to stop their growth. This mutation is common in glioblastoma and makes the cancer grow faster and resist standard treatments.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

36 Participants Needed

AZD1390 + Radiation Therapy for Brain Cancer

Boston, Massachusetts
This study will test an investigational drug called AZD1390 in combination with radiation therapy for the treatment of brain tumors. This is the first time AZD1390 is being given to patients. This study will test safety, tolerability and PK (how the drug is absorbed, distributed and eliminated) of ascending doses of AZD1390 in combination with distinct regimens of radiation therapy
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

180 Participants Needed

Navtemadlin for Brain Cancer

Boston, Massachusetts
This phase I trial studies the side effects and best dose of navtemadlin in treating patients with glioblastoma (brain cancer) that is newly diagnosed or has come back (recurrent). Navtemadlin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

32 Participants Needed

Optune + Radiation & Chemotherapy for Brain Cancer

Boston, Massachusetts
To test the effectiveness and safety of Optune® given concomitantly with radiation therapy (RT) and temozolomide (TMZ) in newly diagnosed GBM patients, compared to radiation therapy and temozolomide alone. In both arms, Optune® and maintenance temozolomide are continued following radiation therapy.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

982 Participants Needed

MRI Scans During Radiation Therapy for Cancer

Boston, Massachusetts
This is a phase 1 study to determine the feasibility and utility of using serial magnetic resonance imaging (MRI) to assess treatment response during and after radiation therapy (standard of care cancer treatment) for participants with advanced esophageal cancer, glioblastoma, prostate cancer, vulvar cancer or pediatric glioma. The research study procedures include three MRI scans (one before, one during, and one after standard of care cancer radiation therapy) for participants with advanced esophageal cancer, glioblastoma, prostate cancer, vulvar cancer or pediatric glioma. The research study procedures include: * Screening for eligibility * Three MRI scans
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

139 Participants Needed

Relatlimab + Nivolumab for Recurrent Glioblastoma

Boston, Massachusetts
This phase II trial compares the safety, side effects and effectiveness of anti-lag-3 (relatlimab) and anti-PD-1 blockade (nivolumab) to standard of care lomustine for the treatment of patients with glioblastoma that has come back after a period of improvement (recurrent). Relatlimab and nivolumab are monoclonal antibodies that may interfere with the ability of tumor cells to grow and spread. Lomustine is a chemotherapy drug and in a class of medications called alkylating agents. It damages the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. Relatlimab and nivolumab may be safe, tolerable, and/or effective compared to standard of care lomustine in treating patients with recurrent glioblastoma.
No Placebo Group

Trial Details

Trial Status:Recruiting

184 Participants Needed

Selinexor + Radiation for Brain Cancer

Boston, Massachusetts
This trial tests the safety and effectiveness of combining selinexor with radiation therapy in children and young adults with aggressive brain tumors. Selinexor is a drug that blocks a protein to stop cancer cells from growing. The study aims to find the best dose and see if this combination can shrink tumors.
No Placebo Group

Trial Details

Trial Status:Recruiting
Age:12 - 21

210 Participants Needed

Adavosertib + Radiation + Temozolomide for Glioblastoma

Boston, Massachusetts
This trial tests the safety and best dose of adavosertib combined with radiation and temozolomide for treating glioblastoma. Adavosertib blocks enzymes needed for tumor growth, while radiation and temozolomide kill cancer cells and stop them from growing. The study aims to find the most effective dose and understand how well this combination works for patients with newly diagnosed or recurrent glioblastoma.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting

74 Participants Needed

Vaccine Therapy + Temozolomide for Glioblastoma

Boston, Massachusetts
This trial studies how well a special vaccine works with a common chemotherapy drug in treating patients with recently found brain cancer. The vaccine helps the immune system fight the cancer, while the chemotherapy attacks the cancer cells directly.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

66 Participants Needed

ERC1671 + GM-CSF + Cyclophosphamide for Glioblastoma

Boston, Massachusetts
This phase II clinical trial studies how well ERC1671 plus Granulocyte-macrophage colony-stimulating factor (GM-CSF) plus Cyclophosphamide with Bevacizumab works compared to Placebo Injection plus Placebo Pill with Bevacizumab in treating patients with recurrent/progressive, bevacizumab naïve glioblastoma multiforme and gliosarcoma (World Health Organization (WHO) grade IV malignant gliomas, GBM).

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

84 Participants Needed

G-CSF for Glioblastoma

Boston, Massachusetts
This research study involves the study of granulocyte colony stimulating factor (G-CSF) in patients with MGMT-methylated glioblastoma multiforme (GBM) that are undergoing standard chemoradiation. The study aims to evaluate G-CSF's effects on brain health and cognitive function. The name of the study drugs involved in this study are: * G-CSF (also called Filgrastim) * Temozolomide (TMZ), a standard of care chemotherapy drug
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Phase 2

60 Participants Needed

Safusidenib for Brain Cancer

Boston, Massachusetts
This trial is testing a new oral medication called safusidenib for patients with certain types of brain tumors that have not responded to other treatments. The drug works by targeting a specific gene mutation to slow down tumor growth. The study will evaluate the safety and effectiveness of different doses of the medication.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

125 Participants Needed

Ribociclib + Everolimus for Brain Tumors

Boston, Massachusetts
This trial is testing whether the combination of ribociclib and everolimus can help children and young adults with aggressive brain tumors live longer. Everolimus is a medication that has been approved for treating various cancers. These drugs are taken by mouth and work by stopping cancer cells from growing. The study focuses on patients whose tumors have specific genetic changes that make them hard to treat with standard therapies.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:12 - 39

100 Participants Needed

Lorlatinib for Brain Tumors

Boston, Massachusetts
The goal of this study is to determine the response of the study drug loratinib in treating children who are newly diagnosed high-grade glioma with a fusion in ALK or ROS1. It will also evaluate the safety of lorlatinib when given with chemotherapy or after radiation therapy.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Early Phase 1
Age:1 - 21

15 Participants Needed

NGM707 + Pembrolizumab for Cancer

Boston, Massachusetts
This trial is testing a new drug called NGM707, both by itself and with another drug, Pembrolizumab. It targets patients with very advanced or spreading solid tumors. The treatment aims to boost the immune system to better fight cancer.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

179 Participants Needed

Why Other Patients Applied

"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

HZ
Arthritis PatientAge: 78

"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

ID
Pancreatic Cancer PatientAge: 40

"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

FF
ADHD PatientAge: 31

"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

IZ
Healthy Volunteer PatientAge: 38

"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

ZS
Depression PatientAge: 51

Lurbinectedin + Irinotecan for Cancer

Boston, Massachusetts
Prospective, open-label, dose-ranging, uncontrolled phase I/II study of Lurbinectedin in combination with irinotecan. The study will be divided into two stages: a Phase I dose escalation stage and a Phase II expansion stage.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

320 Participants Needed

Indoximod + Chemotherapy/Radiation for Pediatric Brain Cancer

Boston, Massachusetts
Indoximod was developed to inhibit the IDO (indoleamine 2,3-dioxygenase) enzymatic pathway, which is important in the natural regulation of immune responses. This potent immune suppressive mechanism has been implicated in regulating immune responses in settings as diverse as infection, tissue/organ transplant, autoimmunity, and cancer. By inhibiting the IDO pathway, we hypothesize that indoximod will improve antitumor immune responses and thereby slow the growth of tumors. The central clinical hypothesis for the GCC1949 study is that inhibiting the pivotal IDO pathway by adding indoximod immunotherapy during chemotherapy and/or radiation is a potent approach for breaking immune tolerance to pediatric tumors that will improve outcomes, relative to standard therapy alone. This is an NCI-funded (R01 CA229646, MPI: Johnson and Munn) open-label phase 2 trial using indoximod-based combination chemo-radio-immunotherapy for treatment of patients age 3 to 21 years who have progressive brain cancer (glioblastoma, medulloblastoma, or ependymoma), or newly-diagnosed diffuse intrinsic pontine glioma (DIPG). Statistical analysis will stratify patients based on whether their treatment plan includes up-front radiation (or proton) therapy in combination with indoximod. Central review of tissue diagnosis from prior surgery is required, except non-biopsied DIPG. This study will use the "immune-adapted Response Assessment for Neuro-Oncology" (iRANO) criteria for measurement of outcomes. Planned enrollment is up to 140 patients.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:3 - 21

140 Participants Needed

Vorinostat + Temozolomide for Brain Cancer

Boston, Massachusetts
This phase I trial is studying the side effects and best dose of vorinostat when given together with temozolomide in treating patients with malignant gliomas. Drugs used in chemotherapy, such as vorinostat and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vorinostat may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vorinostat may help temozolomide work better by making tumor cells more sensitive to the drug. Giving vorinostat together with temozolomide may kill more tumor cells.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

83 Participants Needed

Fimepinostat for Brain Cancer

Boston, Massachusetts
This trial studies how well fimepinostat works in treating patients with newly diagnosed diffuse intrinsic pontine glioma, or medulloblastoma, or high-grade glioma that have come back. Fimepinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Early Phase 1
Age:3 - 39

30 Participants Needed

INCB7839 for Brain Cancer in Children

Boston, Massachusetts
This trial tests INCB7839, a drug that blocks proteins helping cancer cells grow, on children with tough-to-treat brain tumors that have returned or grown after initial treatment. The drug works by stopping a protein needed for tumor growth from being released.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Age:3 - 21

13 Participants Needed

Dabrafenib + Trametinib for Brain Tumors

Boston, Massachusetts
This trial is studying the effects of two cancer medications, dabrafenib and trametinib, in children. These drugs work by stopping signals that make cancer cells grow. Dabrafenib and trametinib have shown benefits in various BRAF-mutant tumors, including melanoma, lung cancer, and thyroid cancer. The goal is to see how these treatments affect children over time.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 4
Age:1 - 99

164 Participants Needed

Sapanisertib + Bevacizumab for Glioblastoma

Charlestown, Massachusetts
This phase I trial studies the side effects and best dose of raptor/rictor-mammalian target of rapamycin (mTOR) (TORC1/2) inhibitor MLN0128 when given in combination with bevacizumab in treating patients with glioblastoma, a type of brain tumor, or a solid tumor that has spread and not responded to standard treatment. TORC1/2 inhibitor MLN0128 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Bevacizumab may also stop the progression of tumors by blocking the growth of new blood vessels necessary for tumor growth.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

50 Participants Needed

APL-101 for Lung Cancer

Boston, Massachusetts
This trial is testing APL-101, a new drug, on patients with specific genetic changes in their cancer. These patients often don't respond to typical treatments. The drug aims to block a protein that helps cancer cells grow and spread.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

497 Participants Needed

Olutasidenib + Temozolomide for Brain Tumors

Boston, Massachusetts
The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation. The main question the study aims to answer is whether the combination of olutasidenib and temozolomide (TMZ) can prolong the life of patients diagnosed with an IDH-mutant HGG.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:12 - 39

60 Participants Needed

BDTX-1535 + Temozolomide for Glioblastoma and Lung Cancer

Boston, Massachusetts
BDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multiple cohort study designed to evaluate the safety, pharmacokinetics (PK), optimal dosage, central nervous system (CNS) activity, and antitumor activity of BDTX-1535. The study population comprises adults with either advanced/metastatic non-small cell lung cancer (NSCLC) with non-classical or acquired epidermal growth factor receptor (EGFR) resistance (EGFR C797S) mutations with or without CNS disease (in Phase 1 and Phase 2), or glioblastoma (GBM) expressing EGFR alterations (Phase 1 only). All patients will self-administer BDTX-1535 monotherapy by mouth in 21-day cycles. Phase 1 enrollment is now complete. Phase 2 is currently enrolling.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

200 Participants Needed

123

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do Glioblastoma clinical trials in Boston, MA pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Glioblastoma clinical trials in Boston, MA work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Glioblastoma trials in Boston, MA 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Boston, MA for Glioblastoma is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Boston, MA several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Glioblastoma medical study in Boston, MA?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Glioblastoma clinical trials in Boston, MA?

Most recently, we added CUE-102 for Glioblastoma, Lorlatinib for Brain Tumors and G-CSF for Glioblastoma to the Power online platform.

Popular Searches

By Condition

Depression Clinical Trials in Massachusetts

Anxiety Clinical Trials in Massachusetts

Schizophrenia Clinical Trials in Massachusetts

ADHD Clinical Trials in Massachusetts

Bipolar Disorder Clinical Trials in Massachusetts

Multiple Sclerosis Clinical Trials in Massachusetts

Autism Clinical Trials in Massachusetts

Treatment Resistant Depression Clinical Trials in Massachusetts

Borderline Personality Disorder Clinical Trials in Massachusetts

Social Anxiety Disorder Clinical Trials in Massachusetts

Parkinson's Disease Clinical Trials in Massachusetts

Alzheimer's Disease Clinical Trials in Massachusetts

By Location

Clinical Trials near Boston, MA

Clinical Trials near Worcester, MA

Clinical Trials near Springfield, MA

Clinical Trials near Burlington, MA

Clinical Trials near Fall River, MA

Clinical Trials near Cambridge, MA

Clinical Trials near North Dartmouth, MA

Clinical Trials near Newton, MA

Clinical Trials near Waltham, MA

Clinical Trials near Watertown, MA

Clinical Trials near Belmont, MA

Clinical Trials near Brockton, MA

Other People Viewed

By Subject

Top Clinical Trials near Boston, MA

Top Clinical Trials near Boston, MA

Top Depression Clinical Trials near Boston, MA

Top Leiomyosarcoma Clinical Trials near Boston, MA

Top Osteoporosis Clinical Trials near Boston, MA

Top Colorectal Cancer Clinical Trials near Boston, MA

Top Breast Cancer Clinical Trials near Boston, MA

Top Lung Cancer Clinical Trials near Boston, MA

Top Prostate Cancer Clinical Trials near Boston, MA

Top Clinical Trials near Jamaica Plain, MA

Top Glioblastoma Clinical Trials

Top Recurrent Glioblastoma Clinical Trials

By Trial

Atezolizumab + Cabozantinib for Glioblastoma

Personalized Cancer Vaccine + RT + Pembrolizumab for Glioblastoma

ITI-1001 for Glioblastoma

NMS-03305293 + Temozolomide for Glioblastoma

Cediranib + Olaparib vs Bevacizumab for Recurrent Glioblastoma

Gene Therapy + Chemoradiotherapy for Glioblastoma

Methimazole for Brain Tumor

C134 Virus Therapy for Glioblastoma

Liposomal Bupivacaine for Post-Surgery Pain in Fibroids

Glide Control for Upper Extremity Amputation

Metabolic Agents After Brain Radiotherapy for Brain Cancer

Focused Ultrasound + Chemotherapy for Pediatric Brain Cancer

Related Searches

Top Glioblastoma Clinical Trials near Anaheim, CA

BioButton Device for Walking Problems

Technology-Enabled Team Care for High Blood Pressure

Top Clinical Trials near Jupiter, FL

Innovative Therapies for Acute Respiratory Distress Syndrome

Radiotherapy Approaches for Oral Cancer

Low Glycemic Index Shake for High Blood Sugar

Top Clinical Trials near Columbia, SC

EscharEx for Venous Leg Ulcers

Eating Patterns for Obesity

Birth Control Pills for Hand and Wrist Injuries

Wingate Test for Performance Enhancement

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial